acetylgalactosamine has been researched along with aminolevulinic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Clausen, VA; Goel, V; Habtemariam, BA; Kim, JB; Robbie, GJ; Simon, AR | 1 |
| Anderson, KE; Balwani, M; Bissell, DM; Bonkovsky, HL; Chen, J; Garg, P; Gouya, L; Harper, P; Horie, Y; Ivanova, A; Kauppinen, R; Keel, SB; Kim, JB; Ko, JJ; Langendonk, JG; Liu, S; Minder, E; Parker, C; Peiró, PA; Penz, C; Phillips, J; Rees, DC; Sardh, E; Silver, SM; Simon, AR; Stein, PE; Stölzel, U; Sweetser, MT; Vaishnaw, A; Vassiliou, D; Ventura, P; Wang, B; Wang, JD; Windyga, J | 1 |
2 trial(s) available for acetylgalactosamine and aminolevulinic acid
| Article | Year |
|---|---|
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Topics: Acetylgalactosamine; Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Injections, Subcutaneous; Male; Middle Aged; Porphobilinogen; Porphyria, Acute Intermittent; Pyrrolidines; Young Adult | 2020 |
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Topics: Acetylgalactosamine; Adult; Aminolevulinic Acid; Double-Blind Method; Fatigue; Female; Humans; Injections, Subcutaneous; Least-Squares Analysis; Liver; Male; Nausea; Pain; Patient Outcome Assessment; Porphobilinogen; Porphyria, Acute Intermittent; Pyrrolidines; Renal Insufficiency, Chronic; RNAi Therapeutics; Transaminases | 2020 |